MeSH D056648 - anti-neutrophil cytoplasmic antibody-associated vasculitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D056647:Systemic vasculitis
0 Companies
0 Drugs
Success rate
D017445:Vascular skin diseases
0 Companies
0 Drugs
Success rate
D056648:
Anti-neutrophil cytoplasmic antibody-associated vasculitis
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Chemocentryx | Avacopan | Tavneos | 2029-12-21 | 2021-10-07 | ||
| Vifor | Avacopan | Tavneos | 2022-01-11 |
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
69%9/13
Phase 3
21%3/14
Approved: 1Overall Success rate: 15%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use